Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of inhaled seralutinib in pulmonary arterial hypertension
jRCT2051230191Phase 3Active, not recruiting
- Sponsor
- GB002, Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Seralutinib arm with Placebo arm (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to Week 24. Started Apr 2024; status: active, not recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2051230191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230191.